Hospital.Help

London – The RNAi therapeutic Vutrisiran can reduce the risk of death and the frequency of cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). This was reported by Marianna Fontana from University College London, who presented the results of the HELIOS-B study at the ESC Congress 2024. They were published simultaneously in the New England Journal of Medicine (NEJM 2024; DOI: 10.1056/NEJMoa240913)….